Does taking vitamin D prevent you from getting respiratory infections? - No Does taking vitamin D in people who had low vitamin D at the start make them less likely to get respiratory infections? - No That said, if you take vitamin D and you do get a respiratory infection, does

Postchemotherapy RPLND This study challenges the routine 1 cm residual mass cut-off in clinical practice, demonstrating that even with residual masses <1 cm, viable tumor (2%) and teratoma (22%) are detected. Is it time to reconsider the RPLND criteria? annalsofoncology.org/article/S0923-…

#SGBCC2025 Optimizing axillary management. Great algorithm by Dr. Cicero Urban, informed by results from the SOUND and INSEMA trials.

🚨 Can We Avoid Surgery in Esophageal Cancer? The SANO Trial Has Answers! 🚨OncoAlert A new ph 3 trial suggests that active surveillance after neoadjuvant chemoradiotherapy (CRT) may be a safe alternative to immediate surgery. Let’s break it down! 🧵⬇️

Just published in Journal of Clinical Oncology the updated ASCO guidelines on fertility preservation in people with #cancer: a must read for all colleagues involved in cancer care to increase awareness on #oncofertility issues OncoAlert Ann Partridge MD, MPH Oncofertility Link: ascopubs.org/doi/10.1200/JC…

Testing out a Paradox / Bias........... Do you enjoy doing polls on X ?

🧬 MSI-H = hallmark of mismatch repair (MMR) deficiency. 🧵 Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric. But not all MSI-H/dMMR tumors are alike: 1️⃣ MSH2/MSH6 loss → ↑ TMB, better ICI response 2️⃣ PTEN/AKT1 mutations → ICI resistance Checkpoint blockade is now 1L in CRC

Kudos to Dr Sanudev Sadanandan for organizing ONCOSCOPE 2025, a groundbreaking conference that raises awareness about Oncology among undergraduates.🎉🙌🎉 Honored to have represented medical oncology, highlighting the progress of cancer treatment over the ages 💉💊⚕️⚕️

1/n..Under the aegis of CRSF - Cancer Research and Statistic Foundation and guidance of Dr (Prof). Vijay Patil, Vanita Noronha, MBBS MD DM, Dr. Kumar sir, our long-awaited study on Triple Metronomic therapy was published in The Cancer Letter. Please read and comment. kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

🎓 Proud moment from #AsterMIMS! Two of our studies by final-year residents were published online at #ASCO25: 🧬 NSCLC study led by Dr. Sreedhar Cherulli highlights disparity in access to targeted therapy despite widespread NGS testing. 🩸 HCC study led by Dr. Sireesh Kumar Ch

🥈 Secured 2nd prize at the Interdepartmental Quiz @ Aster MIMS! With 50+ teams competing, it was a thrilling test of trivia covering health, business, and current affairs. Proud of the teamwork and quick thinking! 💡🧠🔥 #QuizTime #AsterMIMS #TriviaChampions #MedicalQuiz

🧪 NAPOLI-3 Trial: First-Line Treatment in Metastatic Pancreatic Cancer Phase III, randomized, open-label trial 🧬 Study Arms 📌 NALIRIFOX (q2 weeks) Liposomal Irinotecan (nal-IRI) 50 mg/m² Oxaliplatin 60 mg/m² Leucovorin 400 mg/m² 5-FU 2400 mg/m² (46 hr infusion) 🆚 📌

The NCCN has included adjuvant atezolizumab (for 1 year) in the treatment of stage pT2c–III dMMR colon cancer. Given the positive trial results, its inclusion is certainly appropriate. However, the guideline adopts a somewhat conservative stance regarding neoadjuvant ICI use,

NEJM 2025 (ALASCCA): Low-dose aspirin (160 mg) in PI3K-altered stage I–III CRC ↓ 3-yr recurrence (7.7% vs 14.1%, HR 0.49). 🔎 6,397 pts screened → 2,980 sequenced → 1,103 (37%) had PI3K-pathway mutations Hotspot exon 9/20: 17% Other PI3K/PTEN: 20% 📊 NNT: Colon II → weak (42)

💗 HER2CLIMB-05: TUKYSA takes the lead in HER2+ MBC maintenance! 🚀 (PRESS RELEASE) 🧪 Phase 3 | n = 654 | 1st-line maintenance after chemo Arms: 🔹 Tucatinib + trastuzumab + pertuzumab 🔹 Placebo + trastuzumab + pertuzumab 🎯 Primary endpoint met: ✨ Statistically & clinically

🧬 PARP Maintenance After First-Line Chemo Huge PFS benefit… but still no OS signal? A 7-trial meta-analysis across 4013 pts. 🔍 Study Snapshot 🧪 7 RCTs 👩‍⚕️ Advanced-stage EOC (after response to platinum) 🧬 Subgroups: BRCA, HRD, BRCA-wt, HRP 🔪Surgery types: PCS vs NACT 💊